SCHEMBL4823685

SCHEMBL4823685

COC(=O)C(Cc1ccc(-c2ccccc2C(F)(F)F)cc1)NC(=O)c1cc(-c2ccccc2C(F)(F)F)ccc1O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.46
KDR P35968 1/20 0.46
MME P08473 1/20 0.46
TACR3 P29371 1/20 0.46
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
HDAC1 Q13547 4/20 0.44
HDAC6 Q9UBN7 4/20 0.44
MDM4 O15151 1/20 0.44
MDM2 Q00987 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
ELANE P08246 2/20 0.43
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4823689 1.00 CDK2 (0.46) CDK2KDRMMETACR3PPARG
SCHEMBL4825751 0.97 CDK2 (0.48) CDK2KDRMMETACR3PPARG
SCHEMBL4825747 0.97 CDK2 (0.48) CDK2KDRMMETACR3PPARG
SCHEMBL4829612 0.93 CDK2 (0.55) CDK2KDRMDM4MDM2NOS3
SCHEMBL4829625 0.93 CDK2 (0.55) CDK2KDRMDM4MDM2NOS3
SCHEMBL6099342 0.89 MME (0.50) CDK2MMEPPARGPPARA
SCHEMBL6099061 0.87 KIFC1 (0.51) MMEPPARGPPARA
SCHEMBL5926411 0.84 CDK2 (0.55) CDK2KDRTACR3HDAC1HDAC6
SCHEMBL4829792 0.83 CDK2 (0.59) CDK2KDRTACR3HDAC1HDAC6
SCHEMBL4829786 0.83 CDK2 (0.59) CDK2KDRTACR3HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO CDK2 456/4885KDR 1624/4885MME 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.